Boston Scientific Corp (BSX)vsHaemonetics Corporation (HAE)
BSX
Boston Scientific Corp
$43.50
-1.85%
HEALTHCARE · Cap: $60.84B
HAE
Haemonetics Corporation
$120.28
+0.12%
HEALTHCARE · Cap: $5.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1458% more annual revenue ($21.07B vs $1.35B). BSX leads profitability with a 16.6% profit margin vs 7.1%. BSX appears more attractively valued with a PEG of 0.63. BSX earns a higher WallStSmart Score of 62/100 (C+).
BSX
Buy62
out of 100
Grade: C+
HAE
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.2%
Fair Value
$39.17
Current Price
$43.50
$4.33 premium
Margin of Safety
+34.3%
Fair Value
$87.57
Current Price
$120.28
$32.71 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Generating 1.3B in free cash flow
No standout strengths identified
Areas to Watch
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
Expensive relative to growth rate
2.9% earnings growth
Distress zone — elevated risk
7.1% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bull Case : HAE
HAE has a balanced fundamental profile.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Bear Case : HAE
The primary concerns for HAE are PEG Ratio, EPS Growth, Altman Z-Score. A P/E of 57.2x leaves little room for execution misses.
Key Dynamics to Monitor
HAE carries more volatility with a beta of 0.61 — expect wider price swings.
HAE is growing revenue faster at 5.6% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (62/100 vs 50/100), backed by strong 16.6% margins. HAE offers better value entry with a 34.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?